Undisclosed FcR-targeting Nanobody Program(s)

About FcR Therapeutics

FcR Therapeutics is a private, preclinical-stage biotech focused on autoimmune diseases through a novel approach of targeting Fc receptors. The company leverages a proprietary antibody (likely nanobody) platform to develop therapeutics that modulate the dysfunctional interaction between autoantibodies and FcRs, which is a key driver of tissue damage. A significant early validation point is a strategic collaboration announced in 2025 with Grifols, a global leader in plasma medicines, to pioneer recombinant nanobody therapies. The experienced leadership team combines expertise in antibody development and entrepreneurship.

Therapeutic Areas

Other Autoimmune Diseases Drugs